Cadherins seem to play and important role in prostate cancer (PCa) progression. E-cadherin loss of expression has been associated with poor prognosis; P-cadherin's role is still elusive. Although pT3 PCa is often considered Bhigh-risk cancer,^it does not exhibit an uniformly poor prognosis. Herein, we assessed the prognostic value and survival impact of E-cadherin and Pcadherin immunoexpression in pT3 PCa. Radical prostatectomy (RP) specimens from 102 pT3 PCa patients treated between 1991 and 2014 in a single institution were designated for E-cadherin and P-cadherin immunoexpression analysis. A representative block from each specimen was selected for tissue micro-array (TMA) construction, using 3 cores per case. E-cadherin immunoexpression was assessed via a digital image analysis system. For P-cadherin, scoring criteria for HER2 in gastric cancer were used. Clinical records of all patients were reviewed for baseline clinical/pathologic characteristics and follow-up data. Ecadherin-low PCa patients displayed worse disease-specific survival (DSS), although not reaching statistical significance (HR 2.65, 95%CI 0.81-7.88). However, considering the pT3b group only, those with low E-cadherin immunoexpression displayed significantly worse overall-survival (OS) and DSS (HR 3.69, 95%CI 1.18-11.50; HR 5.90, 95%CI 1.40-24.81). No significant differences in survival were found for P-cadherin differential immunoexpression. Furthermore, an association between Ecadherin and P-cadherin immunoexpression (p = 0.019) was found, as among E-cadherin-low PCa, 96.6% were P-cadherin negative. We demonstrated that low E-cadherin immunoexpression discriminates among pT3b PCa patients those with poorer survival and which might benefit from specific therapy. The role of P-cadherin in PCa seems context-dependent deserving further investigation.
Introduction
Prostate cancer (PCa) is widely recognized as one of the most relevant medical conditions in the male population. It represents the most common malignancy and a major cause of cancer-related death among men [1] . In the USA, an estimated 161,360 new cases of PCa were diagnosed and 26,730 deaths due to PCa were expected in 2017 [2] . PCa awareness has increased since the introduction of serum prostate-specific antigen (PSA) testing as a screening tool in the late 1980s [3] [4] [5] , which remains the only clinically implemented diagnostic and follow-up biomarker for PCa [6] . However, due to the frequently indolent course of the disease and the unspecific nature of the test, increased incidence of PSA-detected PCa has been largely associated with cancers that would not progress to an advanced stage and that are considered clinically insignificant [7] . Overdiagnosis has, thus, become a major challenge and ensues overtreatment consequences.
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Nonetheless, PCa encompasses a wide spectrum of clinical outcomes and its natural history is highly variable [8] : in some cases, it progresses to metastatic disease in patients with localized tumor treated radically, whereas in other cases the disease does not progress at all [9] [10] [11] . Patients are advised on treatment based on risk assessment and model equations are often used for this purpose, taking into account preoperative serum PSA, postoperative Gleason score and pathologic stage [12] . However, prediction of progression for the individual patient using these models is still not precise, and additional markers are needed to more accurately target high-risk patients and establish a treatment course [13] . This is well illustrated by locally advanced prostate cancer, which is defined as a tumor that has extended beyond the prostatic gland or into seminal vesicles, but without lymph node involvement or distant metastases, corresponding to pT3 stage in the American Joint Committee on Cancer (AJCC) classification [14] . Although these tumors are often referred to in the literature as high risk cancer [15] , it has been argued that these patients do not present a uniformly poor prognosis after radical prostatectomy [16] . Thus, novel biomarkers might help discriminate among pT3 PCa patients with distinct clinical outcome.
One group of proteins whose altered expression has been associated with tumor invasiveness, metastatic dissemination, and poor patient prognosis is the cadherins superfamily. Cadherins are a large multigene family of transmembrane glycoproteins with a crucial role in homophilic cell-cell adhesion, cell polarity, cell proliferation, migration, and differentiation [17, 18] . E-cadherin has been considered the paradigmatic classical cadherin and is mainly expressed in epithelial tissues. It likely functions as an invasion suppressor gene/protein since its loss of expression, abnormal function, or both, leads to an increased ability of cells to invade neighboring tissues [19] . In addition, E-cadherin downregulation is considered a main indicator of epithelial/mesenchymal phenotype switch, which occurs during epithelial-mesenchymal transition (EMT) [20] . EMT allows for the detachment of tumor cells from the primary site, followed by intravasation into the blood stream, extravasation into distant target organs, and metastases formation [21] [22] [23] . E-cadherin has been consistently demonstrated to be downregulated, silenced or aberrantly expressed in multiple cancer types [24] and its fundamental role in tumorigenesis has been recognized, particularly in breast [25] , prostate [26, 27] , and gastric [28] carcinomas. Indeed, several studies have associated the loss of E-cadherin expression on cell membrane with PCa high histological grade and advanced tumor stage, and therefore with poor prognosis. P-cadherin is another classical cadherin with a crucial role in the conservation of epithelial tissues' structural integrity. It shares about 67% of homology with the E-cadherin protein, differing mainly in its extracellular portion [29, 30] . The cancer-related function of P-cadherin is still an object of debate, as it is considered to be context dependent. Opposite effects have been found for P-cadherin in PCa [31] and the prognostic implications of these findings are still unknown.
Thus, we hypothesized that a significant alteration in Ecadherin and P-cadherin expression (cadherin switch and EMT alterations) might occur at a stage in which prostate adenocarcinoma becomes locally invasive (evolving from pT2 to pT3), which entails substantially less favorable outcome. Because extraprostatic extension usually indicates incurable disease, this stage transition might depend on the acquisition of more effective invasive and metastatic capabilities, eventually related with Ecadherin downregulation and/or P-cadherin upregulation. Nevertheless, it is still unclear whether the evaluation of Ecadherin and P-cadherin expression levels in PCa specimens provides prognostic information, independently of wellrecognized prognostic parameters. Thus, we sought to characterize E-cadherin and P-cadherin expression in a series of pT3 stage PCa patients and further evaluate its association with standard clinical and pathological findings, to assess its potential prognostic value and impact on patient survival.
Material and methods

Patients and samples
In this retrospective study, 102 radical prostatectomy specimens of PCa patients (1999-2014) with pT3 disease were collected from the archives of the Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Portugal. All patients were clinically evaluated and treated by the same multidisciplinary team. Histological slides were reviewed, and Gleason score and prognostic grade groups (based on the 2016 WHO criteria) were assigned by dedicated uropathologists. A standard inclusion procedure was used in all cases, requiring total inclusion of the prostate gland. The block representing the highest Gleason score (index tumor), or the one with the greatest amount of tumor when various blocks presented the same Gleason score, was selected as the representative block for tissue micro-array (TMA) construction. TMAs were built using three representative tumor cores per case. Four-μm sections were then cut from each block for immunostaining.
Clinicopathological data was retrieved from the patients' files, including age and PSA at diagnosis, macroscopic features, tumor size, histological type, perineural and vascular invasion, tumor stage [14] , Gleason score and grade group, and also disease recurrence and last follow-up. Biochemical recurrence was considered as previously described [32] .
This study was approved by the institutional ethics committee of Portuguese Oncology Institute Porto (Comissão de Ética para a Saúde do IPO Porto-Ces 235/2017). Because the study was based on retrospective analysis of archival material, it was exempted from informed consent.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using Ultraview Universal DAB Detection Kit (Ventana), in Benchmark Ultra Platform. Antigen retrieval was performed for 64 min with CC1 buffer (for P-cadherin) and for 56 min with CC2 buffer (for E-cadherin). Primary monoclonal antibodies for Ecadherin (Clone NCH38, 1:50 dilution, Reference M3612, DAKO) and P-cadherin (Clone 56C1, ready to use, Reference ab75442, ABCAM) were used. Hematoxilin was used for nuclear counter staining. Appropriate positive controls were used for each antibody and negative control consisted on omission of primary antibodies. Because all cases analyzed contained nonneoplastic prostatic epithelium, this served as (internal) control as appropriate. However, when the IHC protocols were developed, negative external controls were used. E-cadherin immunoexpression was assessed using a digital image analysis system (GenASIs™, Israel), which quantified membrane immunostaining. Staining intensity was scored 0 to 3, with 0 representing negative staining, 1 representing weak staining, 2 representing intermediate staining, and 3 representing strong staining; the percentage of cells with each staining intensity was assessed, as well. The H-Score for each TMA core was calculated (sum of the products of each immunostaining score by its proportion) and mean H-Score was attributed to each case. In the absence of a validated scoring system to evaluate P-cadherin immunoexpression, the scoring criteria for HER2/neu immunoexpression in gastric adenocarcinoma was adopted [33] . Using these criteria, P-cadherin immunoexpression was scored as positive, negative, or equivocal by two researchers blinded to clinical outcome.
Statistical analysis
Statistical analysis was performed using SPSS Statistics for Windows, version 25.0 (SPSS, Chicago, IL). The chi-square test was used for evaluating associations between biomarkers and clinicopathological variables. Distribution of continuous variables between groups was compared using non-parametric tests (Mann-Whitney test). Survival curves were calculated using the Kaplan-Meier method and Log-Rank test was used to compare survival curves. Hazard ratios (HR) and respective 95% confidence intervals (CI) were estimated using Coxregression models. Statistical significance was set at p < 0.05.
Results
Cohort characterization and biomarker immunoexpression
From the initial study population of 102 tumor specimens, two cases were dismissed from analysis due to lack of sufficient tumor cells in the TMA. The clinicopathological features of the remainder 100 patients are displayed in Table 1 . Median age at diagnosis was 64 years (IQR 60-68) and median pre-operative PSA was 8.6 ng/ml (IQR 6.1-11.6). Upon histological examination, 53% of specimens were graded Gleason score ≤ 7 and 71% displayed pT3a disease. Lymphadenectomy was performed in two patients and one of them presented regional lymph node metastasis.
Illustrative examples of E-cadherin and P-cadherin immunostaining are shown in Fig. 1 . The median number of tumor cells and of 200× fields evaluated per case, as well as respective P30 value (30th percentile) for E-cadherin mean H-score, are provided in Table 1 . For subsequent analyses, PCa cases displaying E-cadherin immunostaining below P30 were considered as having BLow E-Cadherin immunoexpression^, and those above P30 as presenting BHigh E-Cadherin immunoexpression^. This cutoff was chosen after testing several cutoff values taking in consideration the data distribution, i.e., percentiles P5 to P95, using increments of 5% of the distribution. Using this methodology, we found that a P30 cutoff provided the best statistical discrimination in survival functions (see below). Furthermore, grade groups 1 and 2 were designated as BLow grade groups^, and grade groups 3, 4, and 5 as BHigh grade groups^.
Cohort validation
Considering the whole cohort, Gleason score > 7 was associated with positive surgical margins (p = 0.046). As expected, patients with pT3b stage presented significantly worse diseasespecific survival (DSS) compared to pT3a group (HR 4.58, 95% CI 1.49-14.05) (Fig. 2a) . Moreover, patients with pT3b stage displayed worse overall-survival (OS), although it did not reach statistical significance (HR 2.03, 95% CI 0.97-4.25). Patients with high-grade group PCa displayed significantly worse DSS compared to those with low grade group disease (HR 9.65, 95% CI 1.25-74.89) (Fig. 2b) .
Associations between E-cadherin and P-cadherin and clinicopathological features An association was found between E-cadherin and P-cadherin immunoexpression. In the group of patients with low Ecadherin immunoexpression, 96.6% of patients were also Pcadherin negative. Additionally, in the group of patients with equivocal/positive P-cadherin immunoexpression, 93.8% presented high E-cadherin immunoexpression (p = 0.019).
Low E-cadherin immunoexpression was associated with higher serum PSA at diagnosis in pT3a stage patients (p = 0.032). No other significant associations were found between E-cadherin or P-cadherin immunoexpression and age, serum PSA, pT stage, grade group, surgical margins, and perineural or vascular invasion.
Survival analyses
The median follow-up time of the PCa patients enrolled in this study was 150 months and a total of 16 (16%) patients died from PCa. Disease free survival (DFS) was 41.9% at 120 months (44.3% in pT3a patients vs. 35 .0% in pT3b patients) and 39.6% at 150 months. Eleven patients were considered not to have remission after curative-intent radical prostatectomy.
Univariable analysis
Considering the whole cohort Patients with low E-cadherin immunoexpression displayed worse DSS, although it did not reach statistical significance (HR 2.65, 95% CI 0.81-7.88). No significant association with O S o r D F S w a s f o u n d . R e g a r d i n g P -c a d h e r i n immunoexpression, no significant difference was found for OS, DSS, and DFS between patients with negative or equivocal/positive immunoexpression.
Considering only pT3a or pT3b subgroups
Both E-cadherin (Fig. 3a) and P-cadherin (Fig. 3b) immunoexpression were not significantly associated with OS, DSS or DFS in patients with pT3a disease.
However, considering only patients with pT3b disease, those with low E-cadherin immunoexpression displayed significantly worse OS and DSS (HR 3.69, 95% CI 1.18-11.50; and HR 5.90, 95% CI 1.40-24.81, respectively), but not DFS, compared to patients with high E-cadherin immunoexpression (Fig. 4a) . Concerning P-cadherin immunoexpression, no significant differences were found in OS, DSS, and DFS (Fig. 4b) .
Multivariable analysis
Owing to the limited number of events, multivariable analysis was not accomplished.
Discussion
PCa is one of the leading causes of cancer-related morbidity and mortality in men, constituting a major health concern and economic burden. Given its heterogeneous course, outcome prediction remains a challenge. The current focus in PCa biomarker research includes the definition of valid prognostic biomarkers with clinical utility, which may accurately predict patients' outcome after surgical resection and support clinical decision-making for the individual patient, considering the tumor's potential aggressiveness [1, 34] . Specifically for locally advanced prostate cancer, classified as high risk cancer, IQR interquartile range, P30 30th percentile for the E-cadherin mean Hscore, PSA prostate-specific antigen outcome after radical prostatectomy varies greatly [16] , demonstrating the importance of identifying biomarkers able to discriminate patient outcome, even among patients with unfavorable prognosis. Considering the role of cadherins deregulation in cancer progression and previously reported findings in PCa, we aimed to investigate the prognostic impact of E-cadherin and P-cadherin immunoexpression in a cohort of pT3 stage PCa patients submitted to curative-intent radical prostatectomy. Our study analyzed 100 prostatectomy specimens from patients evaluated and treated in a single tertiary hospital, with a median age at diagnosis of 64 years, which is similar to the 66 years reported in literature [35] . Prognostic grade grouping stratified patients according to DSS, as expected [36, 37] , although not reaching statistical significance (Supplementary Figure Online Resource 1) , probably due to sample size. Indeed, when prognostic grade groups were lumped together into high and low, statistical significance emerged concerning DSS. Tumor stage also provided a statistically significant stratification of patients, as pT3b patients experienced significantly worse DSS comparing to pT3a patients, in accordance with the literature [38] . Furthermore, DFS at 120 months was 44.3% in pT3a and 35.0% in pT3b patients, also paralleling previous findings [39] . Thus, despite its limited sample size, this series is validated according to standard clinicopathological parameters.
Interestingly, we showed that pT3b PCa with low E-cadherin immunoexpression displayed worse DSS in univariable analysis, although this was not replicated for pT3a PCa patients. To the best of our knowledge, this is the first study to specifically consider the role of E-cadherin immunoexpression in prognosis stratification of pT3 PCa. Previous studies have demonstrated an association between abnormal or low immunoexpression of this biomarker and poor prognosis in PCa, without stratifying, however, for tumor stage [34, [40] [41] [42] [43] [44] [45] . These findings might be explained by the pivotal role of E-cadherin in critical morphogenetic and differentiation processes during development, and in maintaining integrity and homeostasis in adult tissues, including the prostate gland [46] . Indeed, E-cadherin has been identified as an invasion suppressor gene/protein, and its altered expression is believed to increase the ability of cells to invade neighboring tissues [19] . Moreover, its downregulation is considered a main indicator of EMT, a process by which epithelial cells lose polarity and cell adhesion, transforming into mesenchymal-like cells [20] . EMT precedes the detachment of tumor cells from the primary site, and the formation of secondary lesions and metastases [46] . In this line, quantitative E-cadherin immunoexpression might add valuable independent information to the existing prognostic tools for the pT3b group of patients, allowing for discrimination of more aggressive PCa and assisting in individual clinical management.
The lack of prognostic significance of E-cadherin immunoexpression in pT3a PCa patients might be due to an increasingly important role of E-cadherin underexpression along tumor progression. It is widely acknowledged that pT3a PCa portrays a significantly better prognosis than pT3b PCa, thus suggesting that extension into the seminal vesicles is not Fig. 3 Disease-specific survival according to biomarker expression levels in pT3a prostate cancer patients: a E-cadherin; and b P-cadherin Fig. 4 Disease-specific survival according to biomarker expression levels in pT3b prostate cancer patients: a E-cadherin; and b P-cadherin just a matter of increased tumor invasion capabilities, but also of systemic dissemination. Thus, owing to the pivotal role of EMT in invasion and metastization, we are tempted to speculate whether critically low E-cadherin expression levels might only be attained at more advanced disease stages, including pT3b. This is in accordance with previously reported associations between abnormal or low E-cadherin immunoexpression and high histological grade and advanced tumor stage in PCa, as well as poor prognosis [26, 27, 34, [40] [41] [42] [43] [44] [45] . It should be emphasized, however, that previously published studies on E-cadherin's role in PCa display a considerable heterogeneity among them, including different staining interpretation methods, cutoffs (ranging from 10 to 70%), cohort types and sample sizes, precluding definitive conclusions on this subject. In our study, the use of a digital image analyzer, which is uncommon in precedent literature, provided a quantitative and less biased assessment of Ecadherin immunoexpression and might have offered more precise results. Importantly, this might also facilitate its translation into routine diagnosis settings, improving the homogeneity of assessment, without substantially delaying diagnostic workup.
No association was found between E-cadherin immunoexpression and clinicopathogical features, except for higher serum PSA at diagnosis in patients with low E-cadherin immunoexpression, when considering the pT3a group alone. Bussemakers et al. [47] first reported an association between the reduction of E-cadherin expression and PCa metastatic potential, followed by Umbas et al [48] , who demonstrated an association of this feature with tumor grade and prognosis. Since then, several published studies have examined the association between E-cadherin expression and PCa clinicopathological features, showing that loss of cell membrane E-cadherin expression is associated with high PSA level at diagnosis, high histological grade and advanced tumor stage, as well as poor prognosis (Supplementary Table Online Resource 2) [13, 26, 34, 40-42, 44, 45, 48] . The absence of association between Ecadherin immunoexpression and the aforementioned clinicopathological features in our study could be explained by the strong prognostic stratification provided by tumor stage. This finding further enhances the importance of the discriminative power of E-cadherin immunoexpression as prognostic biomarker in pT3b patients. Unfortunately, multivariable analysis was not possible owning to the limited number of cases, as the sample was already stratified by tumor stage. Nevertheless, given that no significant association was found between E-cadherin immunoexpression and the remainder clinicopathological features, it is not expectable that these variables might interfere with the significant association found between low E-cadherin immunoexpression and worse DSS in pT3b PCa patients.
Concerning P-cadherin immunoexpression, no associations were found with PCa clinicopathological features, DSS, OS, and DFS, as well. Comparing to E-cadherin, P-cadherin has been scarcely studied and opposite effects have been reported for this cadherin in PCa. Indeed, Arena et al. [49] concluded in their study that P-cadherin immunoexpression was increased compared to normal prostate tissue, and Gravdal et al [50] demonstrated that positive membranous staining was significantly associated with higher Gleason score, poorly differentiated cancer and shorter time to bone metastases. Inversely, Jarrard et al [51] showed that P-cadherin expression was absent in all of the poorly differentiated PCa specimens enrolled in their study. Bearing in mind that our specimens were obtained from clinically localized disease, it is possible that PCa exhibits an altered expression of P-cadherin in later stages of the spectrum of disease, which might explain our negative results. Remarkably, Pcadherin is frequently overexpressed in high-grade invasive breast carcinomas and has been reported to correlate with tumor aggressiveness, being considered an established indicator of poor prognosis [52] . It is noteworthy that all cases considered positive in our sample set exhibited a relatively weak Pcadherin immunoexpression, which determined the need to use a qualitative estimation analysis, considered to be more subjective when compared to a quantitative technique.
An association was found between E-cadherin and Pcadherin immunoexpression, as most tumors with low Ecadherin immunoexpression were also P-cadherin negative, and those classified as P-cadherin equivocal/positive presented high E-cadherin immunoexpression. E-cadherin and Pcadherin are co-expressed in a number of adult tissues, including the prostate gland [53] . On the contrary, the induction of Pcadherin in some tumors has been associated with E-cadherin downregulation, which might be part of a process called cadherin switch, which occurs during EMT and correlates with tumor progression [54, 55] . The same has been reported in PCa [50] . In our study, a true cadherin switch was not observed. Once again, such results might be explained by the specific spectrum of the disease in our cohort. It is possible that in our cases E-cadherin is already being downregulated, while P-cadherin's expression would only rise in later stages, allowing for the cadherin switch to be discernible by immunohistochemistry.
This study presents several limitations, given its retrospective nature and small cohort size, which may potentially bias the results. In fact, multivariable analysis was not possible owing to this. Because patients were enrolled over an extended period of time (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , clinical management has changed over the years, which might have impacted on outcome. Moreover, although we have presented data regarding OS, the potential impact of comorbidities was not assessed, as we mostly focused on DSS. Nevertheless, the fact that both pT stage and grade grouping stratified PCa patients according to prognosis, further supports the validity of our findings. In addition, this study is based on a series of patients that were evaluated and treated in a single institution by the same multidisciplinary team, making results extrapolation more difficult, but allowing for homogeneity in patients' staging and clinical management. IHC is a widespread and accessible technique, but its qualitative analysis carries a considerable inter-and intra-observer variation. In our study, variation was diminished using a quantitative analysis method, which improved biomarker quantification and reduced evaluation subjectivity. Unfortunately, this was not possible for Pcadherin immunoexpression assessment. Finally, the use of TMA might be limiting owing to tumor heterogeneity, but we are convinced that assessing three tissue cores from each patient can overcome this potential bias.
Conclusion
In our dataset, low E-cadherin immunoexpression predicted poor outcome in pT3b PCa patients submitted to radical prostatectomy. In this setting, E-cadherin might be a promising disease biomarker, since its assessment might assist in discriminating more aggressive from less aggressive PCa among pT3b patients. In our series, the role of P-cadherin in PCa could not be determined, but it might be context-dependent. The role of E-cadherin and P-cadherin in PCa deserves further investigation and validation in future studies, as it may allow for the improvement and personalization of PCa patient management.
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